2017

The EU Commission's report and accompanying working document on the first annual review of the EU-U.S. Privacy Shield framework states that the framework continues to ensure an adequate level of protection for personal data that is transferred from the EU to the U.S.
 
It also indicates that U.S. authorities have the necessary procedures to ensure the proper functioning of the Privacy Shield, including providing new redress possibilities for EU individuals and instituting appropriate safeguards regarding government access to personal data.
 
The Report states that Privacy Shield-related complaint-handling and enforcement procedures have been properly established.
 
The Report provides recommendations to help ensure the proper functioning of the Privacy Shield. The Report will now be sent to be sent to the European Parliament, the Council, the Article 29 Working Party, and U.S. authorities.
 
The Commission will then work with U.S. authorities to implement its recommendations.

A judge in Colorado has ruled that listing offenders' personal information, such as names and addresses, gives the public the power to punish beyond what the court has deemed appropriate.

He also ruled that the Colorado Sex Offender Registration Act violates the 14th Amendment process of rights.

The judge has argued than an individual assessment should be considered for each case.

The Attorney General's Office could appeal the ruling to the 10th Circuit Court of Appeals.

At a recent Workers' Compensation Education Conference, the senior vice president at PRIUM talked about the impact opioid and heroin use is having on the workers' compensation system.

Within this system, there is a growing acceptance that marijuana - a federally illegal controlled substance - could be an acceptable medical treatment, leading to payers reimbursing for cannabis in at least six states.

Financially prudent from a business standpoint, medicinal marijuana could be necessary in the treatment of injured workers. Businesses should begin working marijuana into risk management programs and evaluating policies regarding testing in preparation for the growing acceptance of its medicinal use.